India banned exports of a malaria drug backed by U.S. President Donald Trump amid a run on supplies globally, even as preliminary findings emerge that the medication isn’t better than regular care in the treatment of the coronavirus.
Exports of hydroxychloroquine will be limited to fulfilling existing contracts, while certain shipments on humanitarian grounds may also be allowed on a case-by-case basis, according to a statement issued Wednesday by the Directorate General of Foreign Trade. The ban also does not apply to factories in its special export zones.
India has some of the world’s largest manufacturers of the finished drug as well as its component ingredients and the move is likely to crimp global supply at a time when the medication is receiving unprecedented global attention.
Hospitals and consumers in the U.S. Are stockpiling the drug after Trump called it a “game changer” in the treatment of the coronavirus and vowed to make it widely available. China, Europe and South Korea recommend it as one of several treatments for Covid-19 patients, while India itself advocates health-care workers take the drug regularly as a preventive measure.
But there is no conclusive scientific evidence that hydroxychloroquine can treat the infection from the novel pathogen. Indeed, a small study published in the Journal of Zhejiang University in China showed that patients who got the medicine didn’t fight off the new coronavirus more often than those who did not get the medicine.
Top scientists, including White House coronavirus task force member Anthony Fauci, have called reports that hydroxychloroquine might work anecdotal, and said they need further study before the pill’s use is encouraged.
As the outbreak spreads around the world and shuts down large parts of the global economy, hundreds of clinical trials are being launched to study the effectiveness of everything from anti-flu drugs and antibody-containing plasma from recovered patients, to traditional Chinese herbal medicine. More than 420,000 people have been infected worldwide and almost 20,000 killed in the widening pandemic.
While the verdict is still out on the treatment’s effectiveness, pharmaceutical companies have been racing to increase production of the cheap and decades-old medicine. Cadila Healthcare Ltd., the Indian company which is world’s largest maker of the drug, has said it plans to boost capacity more than 10-fold to meet the surging global demand.
Malaria, Lupus Drug
Hydroxychloroquine, particularly when given with the antibiotic azithromycin, was put in the spotlight following a controversial, small study of about 40 patients hospitalized with Covid-19 in France. In that study, the drug appeared to help clear the virus from their bodies, based on samples taken from nasal swabs. Experts have criticized the design of the study, calling it interesting but far from definitive.
Hydroxychloroquine and the more-toxic drug it is derived from, chloroquine, are also commonly used to treat rheumatoid arthritis and lupus. Neither drug has been approved by the U.S. Food and Drug Administration to treat Covid-19.
In the Chinese study, one patient treated with the malaria drug progressed to severe disease. Four patients given the medicine developed diarrhea and signs of potential liver damage, compared with three getting conventional treatment.
The researchers concluded that additional studies using larger numbers of patients are needed to fully investigate the drug’s risks and benefits.
More coronavirus coverage from Coins2Day:
—All the moves the Fed is making to bolster the economy
—2020 Tokyo Olympics will be delayed by about one year due to coronavirus
—Which stores are open—and closed—during the coronavirus pandemic in the U.S.?
—As the U.K. Goes into lockdown, London faces isolation—and clear skies
—17 companies that are hiring during the coronavirus crisis
—President of the Tenement Museum on what we can learn from previous pandemics
—Listen to Leadership Next, a Coins2Day podcast examining the evolving role of CEO
—WATCH: World leaders and health experts on how to stop the spread of COVID-19
Subscribe to Outbreak, a daily newsletter roundup of stories on the coronavirus pandemic and its impact on global business. It’s free to get it in your inbox.